

# Evaluation of PD-L1 Expression and Associated Tumor-Squamous Cell Carcinoma

Clinical Cancer Research

22, 704-713

DOI: [10.1158/1078-0432.ccr-15-1543](https://doi.org/10.1158/1078-0432.ccr-15-1543)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The prognostic value of systemic and local immunization in patients with laryngeal squamous cell carcinoma. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7177-7185.	1.0	58
2	Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, , e277-e282.	1.8	2
3	Basic Overview of Current Immunotherapy Approaches in Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 298-308.	1.8	115
4	T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities. <i>Frontiers in Immunology</i> , 2016, 7, 353.	2.2	77
5	Current understanding of the tumor microenvironment of laryngeal dysplasia and progression to invasive cancer. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2016, 24, 121-127.	0.8	18
6	The promise of immunotherapy in head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2016, 27, 1675-1685.	0.6	95
7	Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer. <i>Journal of Histochemistry and Cytochemistry</i> , 2016, 64, 587-600.	1.3	30
8	Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. <i>Pathology</i> , 2016, 48, 574-580.	0.3	59
9	PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. <i>Scientific Reports</i> , 2016, 6, 36956.	1.6	196
10	Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma. <i>Oncolmmunology</i> , 2016, 5, e1181252.	2.1	52
11	Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers. <i>Current Treatment Options in Oncology</i> , 2016, 17, 40.	1.3	34
12	High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. <i>Lung Cancer</i> , 2017, 104, 1-6.	0.9	144
13	Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma. <i>Oncolmmunology</i> , 2017, 6, e1269047.	2.1	47
14	Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1199-1204.	2.0	25
15	TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)?: <i>Head and Neck Pathology</i> , 2017, 11, 354-363.	1.3	67
16	PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs. <i>Cancer Research</i> , 2017, 77, 6365-6374.	0.4	77
17	Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 527-533.	0.6	47
18	The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis. <i>Oncolmmunology</i> , 2017, 6, e1356148.	2.1	247

#	ARTICLE	IF	CITATIONS
19	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 311-335.	2.4	530
20	A high ratio of IL-12R $\beta$ 2-positive tumor-infiltrating lymphocytes indicates favorable prognosis in laryngeal cancer. <i>Oral Oncology</i> , 2017, 74, 148-156.	0.8	9
21	Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy. <i>Oncolimmunology</i> , 2017, 6, e1341030.	2.1	36
22	The pattern and clinicopathological correlates of programmed death-ligand 1 expression in cutaneous squamous cell carcinoma. <i>British Journal of Dermatology</i> , 2017, 176, 1354-1356.	1.4	29
23	Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Head and Neck Squamous Cell Carcinoma. <i>Translational Oncology</i> , 2017, 10, 10-16.	1.7	64
24	The tissue distribution and significance of B7-H4 in laryngeal carcinoma. <i>Oncotarget</i> , 2017, 8, 92227-92239.	0.8	10
25	Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5745-5754.	1.0	14
26	Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. <i>Breast Cancer Research</i> , 2017, 19, 91.	2.2	90
27	miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression. <i>Oncotarget</i> , 2017, 8, 62143-62153.	0.8	46
28	Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 92699-92714.	0.8	29
29	PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. <i>Oncolimmunology</i> , 2018, 7, e1435226.	2.1	36
30	Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. <i>Seminars in Cancer Biology</i> , 2018, 52, 228-240.	4.3	314
31	Prognostic significance of tumor-infiltrating lymphocytes in nondisseminated nasopharyngeal carcinoma: A large-scale cohort study. <i>International Journal of Cancer</i> , 2018, 142, 2558-2566.	2.3	73
32	Programmed death ligand-1 expression as immunotherapeutic target in sinonasal cancer. <i>Head and Neck</i> , 2018, 40, 818-827.	0.9	39
33	Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharyngeal, and Hypopharyngeal Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, e79-e85.	0.6	32
34	PD-L1 and Other Immunological Diagnosis Tools. , 2018, , 371-385.		2
35	Combined inhibition of JAK1,2/Stat3/PD-L1 signaling pathway suppresses the immune escape of castration-resistant prostate cancer to NK cells in hypoxia. <i>Molecular Medicine Reports</i> , 2018, 17, 8111-8120.	1.1	36
36	IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. <i>Gut</i> , 2018, 67, 320-332.	6.1	381

#	ARTICLE	IF	CITATIONS
37	Biological predictors of radiosensitivity in head and neck squamous cell carcinoma. <i>Clinical Oral Investigations</i> , 2018, 22, 189-200.	1.4	29
38	PD-L1 is a positive prognostic factor in squamous cell carcinoma of the nasal vestibule. <i>Rhinology</i> , 2018, 56, 255-260.	0.7	1
39	Significance of PD-L1 Expression in Tongue Cancer Development. <i>International Journal of Medical Sciences</i> , 2018, 15, 1723-1730.	1.1	17
40	From VA Larynx to the future of chemoselection: Defining the role of induction chemotherapy in larynx cancer. <i>Oral Oncology</i> , 2018, 86, 200-205.	0.8	13
41	Low PD-L1 Expression Strongly Correlates with Local Recurrence in Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma after Radiation-Based Therapy. <i>Cancers</i> , 2018, 10, 374.	1.7	19
42	The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. <i>Oral Oncology</i> , 2018, 86, 81-90.	0.8	95
43	Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment. <i>Head and Neck</i> , 2018, 40, 2007-2019.	0.9	47
44	Pediatric Cancer Immunotherapy: Opportunities and Challenges. <i>Paediatric Drugs</i> , 2018, 20, 395-408.	1.3	76
45	Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27313.	0.8	11
46	Microbial biomarkers for immune checkpoint blockade therapy against cancer. <i>Journal of Gastroenterology</i> , 2018, 53, 999-1005.	2.3	15
47	Pre-treatment CD8 <sup>+</sup> tumour-infiltrating lymphocyte density predicts distant metastasis after definitive treatment in patients with stage III/IV hypopharyngeal squamous cell carcinoma. <i>Clinical Otolaryngology</i> , 2018, 43, 1312-1320.	0.6	27
48	PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2019, 160, 93-99.	1.1	23
49	Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis. <i>Aging</i> , 2019, 11, 501-522.	1.4	25
50	Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1443-1454.	2.0	13
51	Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting. <i>Frontiers in Oncology</i> , 2019, 9, 827.	1.3	126
52	Clinical relevance and significance of programmed death-ligand 1 expression, tumor-infiltrating lymphocytes, and p16 status in sinonasal squamous cell carcinoma. <i>Cancer Management and Research</i> , 2019, Volume 11, 4335-4345.	0.9	23
53	Identification of miR-145-Centered Competing Endogenous RNA Network in Laryngeal Squamous Cell Carcinoma. <i>Proteomics</i> , 2019, 19, e1900020.	1.3	15
54	High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2823.	1.8	39

#	ARTICLE	IF	CITATIONS
55	Assessment of tumor-associated immune cells in laryngeal squamous cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1761-1772.	1.2	22
56	Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment. <i>Journal of Clinical Pathology</i> , 2019, 72, 542-549.	1.0	26
57	PD-1 and PD-L1 Expression Predicts Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is Associated with HPV Infection. <i>Journal of Cancer</i> , 2019, 10, 937-948.	1.2	39
58	Expression of vimentin (VIM) and metastasis-associated 1 (MTA1) protein in laryngeal squamous cell carcinoma are associated with prognostic outcome of patients. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2019, 40, 487-493.	0.6	8
59	SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Journal of Translational Medicine</i> , 2019, 17, 429.	1.8	5
60	PD-L1 Detection—Pearls and Pitfalls Associated With Current Methodologies Focusing on Entities Relevant to Dermatopathology. <i>American Journal of Dermatopathology</i> , 2019, 41, 539-565.	0.3	8
61	Programmed death ligand 1 and CD8+ immune cell infiltrates in resected primary tracheal malignant neoplasms. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 691-698.	0.6	12
62	Molecular and immunologic analysis of laryngeal squamous cell carcinoma in smokers and non-smokers. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2019, 40, 213-217.	0.6	9
63	The value of immunotherapy in head and neck cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 35-43.	1.4	14
64	Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 102, 104560.	0.8	21
65	Tumor Infiltrating Lymphocytes and CD8+ T Cell Subsets as Prognostic Markers in Patients with Surgically Treated Laryngeal Squamous Cell Carcinoma. <i>Head and Neck Pathology</i> , 2020, 14, 689-700.	1.3	19
66	The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 1721.	2.2	61
67	Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7032.	1.8	20
68	Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 22, 298-309.	2.3	181
69	Postoperative radiotherapy for laryngeal cancer. The prognostic role of programmed death-ligand 1: An immune microenvironment-based cluster analysis. <i>Pathology Research and Practice</i> , 2020, 216, 153120.	1.0	12
70	An increase of CD8+ T cell infiltration following recurrence is a good prognosticator in HNSCC. <i>Scientific Reports</i> , 2020, 10, 20059.	1.6	34
71	<p>Role of GLUT-1 in the Upregulation of PD-L1 Expression After Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11221-11235.	1.0	11
72	&lt;p&gt;Prognostic Significance of PD-L1 Expression and Its Tumor-Intrinsic Functions in Hypopharyngeal Squamous Cell Carcinoma&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 5893-5902.	0.9	13

#	ARTICLE	IF	CITATIONS
73	Programmed Death Ligand 1 Expression in Laryngeal Squamous Cell Carcinomas and Prognosis. <i>BMC Clinical Pathology</i> , 2020, 13, 2632010X2096484.	0.7	4
74	CD8+ Tumour-Infiltrating Lymphocytes and Tumour Microenvironment Immune Types as Biomarkers for Immunotherapy in Sinonasal Intestinal-Type Adenocarcinoma. <i>Vaccines</i> , 2020, 8, 202.	2.1	15
75	Low expression of miR-20b-5p indicates favorable prognosis in laryngeal squamous cell carcinoma, especially in patients with non-infiltrated regional lymph nodes. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2020, 41, 102563.	0.6	7
76	Prognostic role of programmed death ligand 1 (PD-L1) and the immune microenvironment in laryngeal carcinoma. <i>Oral Oncology</i> , 2020, 108, 104836.	0.8	22
77	Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 268.	1.3	68
78	Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2020, 10, 2662.	1.6	14
79	Biomarkers for immunotherapy response in head and neck cancer. <i>Cancer Treatment Reviews</i> , 2020, 84, 101977.	3.4	153
80	Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression. <i>Head and Neck Pathology</i> , 2020, 14, 951-965.	1.3	11
81	Transcriptomic and Immunophenotypic Characterization of Tumor Immune Microenvironment in Squamous Cell Carcinoma of the Oral Tongue. <i>Head and Neck Pathology</i> , 2021, 15, 509-522.	1.3	7
82	Prognostic impact of neutrophils-to-lymphocytes ratio (NLR), PD-L1 expression, and tumor immune microenvironment in laryngeal cancer. <i>Annals of Diagnostic Pathology</i> , 2021, 50, 151657.	0.6	21
83	Bioinformatics analysis identifies COL1A1, THBS2 and SPP1 as potential predictors of patient prognosis and immunotherapy response in gastric cancer. <i>Bioscience Reports</i> , 2021, 41, .	1.1	16
84	The Potential Regulatory Roles of Circular RNAs in Tumor Immunology and Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 617583.	2.2	20
85	PKD3 promotes metastasis and growth of oral squamous cell carcinoma through positive feedback regulation with PD-L1 and activation of ERK-STAT1/3-EMT signalling. <i>International Journal of Oral Science</i> , 2021, 13, 8.	3.6	15
86	PD-L1 expression in recurrent head and neck squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 343-351.	0.8	6
87	Tumor-Infiltrating Lymphocytes in the Tumor Microenvironment of Laryngeal Squamous Cell Carcinoma: Systematic Review and Meta-Analysis. <i>Biomedicines</i> , 2021, 9, 486.	1.4	28
88	TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 665265.	1.8	6
89	Potential prognostic value of PD-L1 and NKG2A expression in Indonesian patients with skin nodular melanoma. <i>BMC Research Notes</i> , 2021, 14, 206.	0.6	1
90	Histologic evaluation of host immune microenvironment and its prognostic significance in oral tongue squamous cell carcinoma: a comparative study on lymphocytic host response (LHR) and tumor infiltrating lymphocytes (TILs). <i>Pathology Research and Practice</i> , 2021, 228, 153473.	1.0	4

#	ARTICLE	IF	CITATIONS
91	Characterization of the Immune Cell Infiltration Profile in Pancreatic Carcinoma to Aid in Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 677609.	1.3	7
92	Prognostic and Therapeutic Implications of Immune Classification by CD8+ Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Sinonasal Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6926.	1.8	12
93	An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment. <i>Frontiers in Pharmacology</i> , 2021, 12, 707930.	1.6	12
94	Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer. <i>Biomolecules</i> , 2021, 11, 970.	1.8	4
95	Gene Model Related to m6A Predicts the Prognostic Effect of Immune Infiltration on Head and Neck Squamous Cell Carcinoma. <i>Journal of Oncology</i> , 2021, 2021, 1-11.	0.6	1
96	Identification of Immune Cell Infiltration Landscape and Their Prognostic Significance in Uveal Melanoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 713569.	1.8	12
97	Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis. <i>Molecules</i> , 2021, 26, 4848.	1.7	5
98	YAP/STAT3 promotes the immune escape of larynx carcinoma by activating VEGFR1-TGF $\beta$ <sup>2</sup> signaling to facilitate PD-L1 expression in M2-like TAMs. <i>Experimental Cell Research</i> , 2021, 405, 112655.	1.2	4
99	High PD-L1 Expression on Tumor Cells Indicates Worse Overall Survival in Advanced Oral Squamous Cell Carcinomas of the Tongue and the Floor of the Mouth but Not in Other Oral Compartments. <i>Biomedicines</i> , 2021, 9, 1132.	1.4	7
100	Biomarkers of laryngeal squamous cell carcinoma: a review. <i>Annals of Diagnostic Pathology</i> , 2021, 54, 151787.	0.6	15
101	Immunologic "Cold" Squamous Cell Carcinomas of the Head and Neck Are Associated With an Unfavorable Prognosis. <i>Frontiers in Medicine</i> , 2021, 8, 622330.	1.2	23
102	Infiltrating immune cells are associated with radiosensitivity and favorable survival in head and neck cancer treated with definitive radiotherapy. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2020, 129, 612-620.	0.2	10
103	A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer. <i>Medical Science Monitor</i> , 2020, 26, e925583.	0.5	14
104	Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0179536.	1.1	34
105	Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping. <i>Oncotarget</i> , 2017, 8, 46756-46768.	0.8	41
106	Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 66178-66194.	0.8	50
107	Towards tumor immunodiagnostics. <i>Annals of Translational Medicine</i> , 2016, 4, 263-263.	0.7	11
108	PD-L1 as a biomarker in NSCLC: challenges and future directions. <i>Annals of Translational Medicine</i> , 2017, 5, 375-375.	0.7	35



#	ARTICLE	IF	CITATIONS
109	Quantitative analysis and study of the mRNA expression levels of apoptotic genes BCL2, BAX and BCL2L12 in the articular cartilage of an animal model of osteoarthritis. <i>Annals of Translational Medicine</i> , 2018, 6, 243-243.	0.7	10
110	Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer. <i>Annals of Translational Medicine</i> , 2018, 6, 241-241.	0.7	90
111	Alternative Splicing Detection Tool—a novel PERL algorithm for sensitive detection of splicing events, based on next-generation sequencing data analysis. <i>Annals of Translational Medicine</i> , 2018, 6, 244-244.	0.7	17
112	PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2017, 37, 1417-1424.	0.5	51
113	Protein kinase D3 regulates the expression of the immunosuppressive protein, PD-L1, through STAT1/STAT3 signaling. <i>International Journal of Oncology</i> , 2020, 56, 909-920.	1.4	13
114	Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. <i>Translational Lung Cancer Research</i> , 2015, 4, 743-51.	1.3	31
115	Multi-Field-of-View Deep Learning Model Predicts Non-small Cell Lung Cancer Programmed Death-Ligand 1 Status from Whole-Slide Hematoxylin and Eosin Images. <i>Journal of Pathology Informatics</i> , 2019, 10, 24.	0.8	70
116	Effect of Programmed Death-Ligand 1 in Cancer-Associated Fibroblasts on Advanced Laryngeal Squamous Cell Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110464.	0.8	0
117	Identification of novel subtypes based on ssGSEA in immune-related prognostic signature for tongue squamous cell carcinoma. <i>Cancer Medicine</i> , 2021, 10, 8693-8707.	1.3	21
118	Potential role of immune cell genetic variants associated with tumor microenvironment response in laryngeal squamous cell carcinoma (LSCC) in terms of clinicopathological features. <i>Pathology Research and Practice</i> , 2021, 228, 153665.	1.0	1
119	Pembrolizumab in the first-line treatment of advanced head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1321-1331.	1.1	11
120	<i>Anatomopathologie</i> , 2019, , 31-46.		0
121	Bağ Boyun Skuamöz Hücreli Kanserlerde T4m1r 0nfiltrate Edici Lenfosit Yoğunluğunun Histopatolojik Parametrelerle Karşılaştırılması ve Prognoz Açısına Etkisi. <i>Sisli Etfal Hastanesi Tıp Bulteni</i> , 2019, 54, 438-443.	0.1	0
122	Relationship between local and systemic inflammatory response and prognosis in laryngeal squamous cell carcinoma. <i>İstanbul Kültür Sanat Vakfı Tıp Dergisi</i> , 2019, 7, 180-184.	0.1	3
123	PD-L1 and CD8-Tumor-Infiltrating Lymphocytes Expression in Laryngeal Squamous Cell Carcinoma. <i>ARS Medica Tomitana</i> , 2020, 26, 137-144.	0.0	0
124	The Role of B Cells in Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 5383.	1.7	10
125	PD-L1 and survival in oral cavity squamous cell carcinoma. <i>Parodontologiya</i> , 2020, 25, 287-294.	0.1	1
126	Characterization of epithelial cells, connective tissue cells and immune cells in human upper airway mucosa by immunofluorescence multichannel image cytometry: a pilot study. <i>Histochemistry and Cell Biology</i> , 2021, 155, 405-421.	0.8	7



#	ARTICLE	IF	CITATIONS
127	CD8 + T Cell Infiltration Predicts Chemoradiosensitivity in Nasopharyngeal or Oropharyngeal Cancer. <i>Laryngoscope</i> , 2021, 131, E1179-E1189.	1.1	9
128	Vaccine-Based Immunotherapy for Head and Neck Cancers. <i>Cancers</i> , 2021, 13, 6041.	1.7	16
129	Tumor budding to investigate local invasion, metastasis and prognosis in temporal bone squamous cell carcinoma. <i>Pathology Research and Practice</i> , 2022, 229, 153719.	1.0	8
130	Pyroptosis-related gene mediated modification patterns and immune cell infiltration landscapes in cutaneous melanoma to aid immunotherapy. <i>Aging</i> , 2021, 13, 24379-24401.	1.4	12
131	Tumour-infiltrating lymphocytes in oropharyngeal cancer: a validation study according to the criteria of the International Immuno-Oncology Biomarker Working Group. <i>British Journal of Cancer</i> , 2022, 126, 1589-1594.	2.9	22
132	Characterization of epigenomic alterations in HPV16+ head and neck squamous cell carcinomas. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, , cebp.EPI-21-0922-A.2021.	1.1	6
133	Characteristics of the Immune Cell Infiltration Landscape in Gastric Cancer to Assistant Immunotherapy. <i>Frontiers in Genetics</i> , 2021, 12, 793628.	1.1	8
134	Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis. <i>Molecular Diagnosis and Therapy</i> , 2022, , 1.	1.6	2
135	Comprehensive analysis of immune cell infiltration and significant genes in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2022, 126, 105755.	0.8	5
136	Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 847350.	1.3	6
137	The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma. <i>Journal of Liver Cancer</i> , 2022, 22, 40-50.	0.3	0
138	Development and Validation of an Immune-Related Signature for the Prediction of Recurrence Risk of Patients With Laryngeal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 683915.	1.3	8
139	Autoimmunity regulation within the tumor microenvironment. , 2022, , 51-71.		0
141	Association of immune response with overall and disease-free survival in laryngeal squamous cell carcinomas. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2022, 43, 103477.	0.6	0
142	Tumor Infiltrating Lymphocytes are Prognostic Factors and Can Be Markers of Sensitivity to Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 1271-1278.	0.5	7
143	Understanding the tumor microenvironment in head and neck squamous cell carcinoma. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	10
144	The Immune Cell Infiltration Patterns and Characterization Score in Bladder Cancer to Identify Prognosis. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
145	Moesin Serves as Scaffold Protein for PD-L1 in Human Uterine Cervical Squamous Carcinoma Cells. <i>Journal of Clinical Medicine</i> , 2022, 11, 3830.	1.0	5

#	ARTICLE	IF	CITATIONS
146	The Multi-Omics Landscape and Clinical Relevance of the Immunological Signature of Phagocytosis Regulators: Implications for Risk Classification and Frontline Therapies in Skin Cutaneous Melanoma. <i>Cancers</i> , 2022, 14, 3582.	1.7	0
147	PD-L1 and the Clinical Outcomes of Ovarian Cancer: Meta-Analysis and Bioinformatical Analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 2285-2290.	0.5	0
148	Core immune cell infiltration signatures identify molecular subtypes and promote precise checkpoint immunotherapy in cutaneous melanoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
149	Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy. <i>Cancer Research</i> , 2022, 82, 3532-3548.	0.4	14
150	During early stages of cancer, neutrophils initiate anti-tumor immune responses in tumor-draining lymph nodes. <i>Cell Reports</i> , 2022, 40, 111171.	2.9	22
151	Biomarkers for Immunotherapy in Poorly Differentiated Sinonasal Tumors. <i>Biomedicines</i> , 2022, 10, 2205.	1.4	5
152	Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
153	lncRNAs AC156455.1 and AC104532.2 as Biomarkers for Diagnosis and Prognosis in Colorectal Cancer. <i>Disease Markers</i> , 2022, 2022, 1-13.	0.6	2
155	Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab. <i>Cancer Management and Research</i> , 0, Volume 14, 3293-3302.	0.9	2
156	A novel prognostic model related to oxidative stress for treatment prediction in lung adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
157	Comparison of PD-L1 and VISTA expression status in primary and recurrent/refractory tissue after (chemo)radiotherapy in head and neck cancer. <i>Strahlentherapie Und Onkologie</i> , 0, , .	1.0	0
158	PD-1 and PD-L1 Expression Levels as a Potential Biomarker of Chronic Rhinosinusitis and Head and Neck Cancers. <i>Journal of Clinical Medicine</i> , 2023, 12, 2033.	1.0	1
169	The role of radiotherapy in tumor immunity and the potential of PET/CT in detecting the expression of PD-1/PD-L1. <i>Japanese Journal of Radiology</i> , 0, , .	1.0	0